Sharemaestro Newsreel

Nuvation Bio (NUVB) Could Be 69% Undervalued On Earnings And IBTROZI Data Focus

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Laura HansenChief Executive Officer - Ryan WattsChief Commercial Officer - Katie PengChief Operating and Financial Officer - Alexander SchuthChief Medical Officer, Head of Development - …

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. …

Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across …

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced a secondary public offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P., an existing shareholder. BridgeBio itself is not selling any shares and will not receive any proceeds from this offering. William Blair, …

KKR Proposes Sale of 5 Million BridgeBio Pharma Shares in Offering

BridgeBio Pharma (BBIO) announced a secondary public offering of 5,000,000 shares of its common stock, to be sold by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not sell any shares in this transaction and will not receive any proceeds. The offering is subject …

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours

Daré Bioscience reported a narrowed Q2 2026 net loss of $3.0 million, down from $4.0 million year-over-year, with revenue reaching $0.2 million. The company's stock initially fell but then surged 21.2% after hours, as investors reacted positively to progress in commercialization with new product …

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

This article highlights bullish sentiments from analysts for two healthcare stocks: Aura Biosciences Inc (AURA) and Corbus Pharmaceuticals (CRBP). LifeSci Capital and H.C. Wainwright maintained Buy ratings for Aura Biosciences, projecting a significant upside. Mizuho Securities and RBC Capital also reiterated Buy ratings for …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …

Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips

Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …

Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants

Farallon Capital Management, L.L.C., along with associated investment partnerships and individuals, has disclosed a 9.7% beneficial ownership in Minerva Neurosciences (NERV). This stake comprises 4,730,000 shares of common stock, including 2,365,000 directly held common shares and shares acquirable through 5,000 Preferred Tranche A Warrants. …

Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares

Damora Therapeutics Director Andrew Cheng was granted stock options to purchase 30,350 ordinary shares on August 12, 2026, as revealed in a recent SEC Form 4 filing. The options have an exercise price of $31 per share and will vest in equal monthly installments …

Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results

Elicio Therapeutics (NASDAQ:ELTX) announced its quarterly earnings, reporting a loss of $0.43 per share, which surpassed analyst estimates by $0.11. Despite a 2.9% rise in shares following the announcement, the stock remains significantly below its 52-week high, with a market capitalization of $60.1 million. …

BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price

BioCardia's President and CEO, Peter Altman, recently purchased 1,900 shares of the company's common stock at a weighted average price of $0.92 per share. This open-market transaction, which occurred on August 13, 2026, increased his direct holdings to 375,785 shares. The purchase was not …

Scholar Rock (SRRK) Stock Looks Priced At A Premium Today

Aurinia Pharmaceuticals (AUPH) Earnings And Buyback Put Fair Value Back In Focus

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) reported a Q2 loss of $4.68 per share, missing the Zacks Consensus Estimate of a $3.18 loss, and revenues of -$1.47 million, significantly below the estimated figures. The company's shares have fallen 19.1% year-to-date, contrasting with the S&P 500's 13.2% gain. …

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

Capricor Therapeutics (CAPR) Q2 Earnings Miss; Shares Rise Amid Mixed Signals

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Satellos Bioscience: Q2 Earnings Snapshot

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing

Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 13,564,149 shares, or 6.4%, of Revolution Medicines, Inc. (RVMD) common stock, according to a recent Schedule 13G/A filing. This includes 13,550,796 shares and 120,085 common stock purchase warrants, with the …

Satellos Q2 loss widens to $11.7M, EPS misses estimates

Satellos Bioscience reported a Q2 2026 net loss of $11.7 million, or $0.56 per share, missing analyst estimates due to significantly increased R&D spending on its Phase 2 DMD clinical trials. Despite the widening loss, the company's cash reserves rose to $61.8 million, providing …

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc. announced its Q2 2026 financial results, reporting a strong cash position of $61.8 million and progress in its clinical trials for SAT-3247, a drug candidate for Duchenne muscular dystrophy (DMD). The company highlighted favorable safety data from the TRAILHEAD adult DMD …

Satellos reports stable strength in four-adult Duchenne study

Satellos reported its second quarter 2026 financial results, including a net loss of $11.7 million, and provided updates on its clinical progress for SAT-3247 in Duchenne muscular dystrophy (DMD). The company highlighted stable strength and reduced muscle fat in a Phase 2 adult DMD …

Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash

Satellos Bioscience reported increased net losses in the first half of 2026 due to higher R&D and G&A expenses, driven by advancing its Duchenne muscular dystrophy (DMD) clinical programs, SAT-3247. Despite widening losses, the company significantly strengthened its cash position to $61.8 million through …

Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary

Estrella Immunopharma, Inc. reported a net loss of $(2.31M) for the second quarter of 2026, with a loss per share of $(0.05). The company remains pre-revenue, driven by ongoing development and corporate expenses. Key highlights include progress in clinical trials, significant milestones in a …

MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary

MapLight Therapeutics (MPLT) reported a net loss of $60.2 million and a loss per share of $(1.32) for the second quarter of 2026, remaining pre-revenue. The increased loss compared to Q2 2025 was due to a significant ramp in clinical trial activity and operational …

Korro Bio director Jean Francois Formela sells $29,916 in shares

Korro Bio director Jean Francois Formela sold 2,143 shares of the company's common stock for approximately $29,916 on August 11, 2026, under a Rule 10b5-1 trading plan. Despite recent volatility and a 67% year-to-date return, InvestingPro analysis suggests the stock may be overvalued. The …

Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan

Korro Bio director Jean Francois Formela's affiliated funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 2,143 shares of Korro Bio common stock on August 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan …